Cannabidiol (CBD) is a naturally occurring compound found in the resinous flower of cannabis. There is growing clinical and anecdotal evidence supporting the therapeutic properties of CBD. A recent report by the World Health Organization (WHO), published on June 2018, details preliminary evidence around its treatment potential for various serious health conditions, while also deeming CBD safe and non-addictive, with no public abuse potential.
CBD is closely related to another important medicinally active cannabinoid found in the cannabis plant, Tetrahydrocannabinol (THC), the compound that causes the high that cannabis is famous for. THC and CBD are the two components of cannabis that have been most studied by scientists to date, though there is growing data about the potential health benefits of other cannabinoids as well. There is significant clinical and anecdotal data that support the significant therapeutic health benefits of both CBD and THC. But unlike THC, CBD is not psychoactive, meaning it does not make a person feel “high” or intoxicated. This is because CBD and THC act in different ways on different receptors in the brain and body. Given increasing evidence about the therapeutic potential of CBD, its non-psychoactive nature and broad availability, CBD is emerging as a new treatment option across a multitude of health conditions.
CBD interacts with our body in a variety of ways, specifically by mimicking and augmenting the effects of the endogenous neurotransmitters in our bodies called “endocannabinoids” - so named because of their similarity to the cannabinoid compounds found in the cannabis plant – or “phytocannabinoids” (Link to What are Phytocannabinoids and how are they different than Endocannabinoids? content below) CBD is one of more than a hundred and fifty phytocannabinoids naturally occurring in the cannabis plant. Endocannabinoids and phytocannabinoids both interact with a major biological regulatory system called the “endocannabinoid system”, or ECS.